Portable Low‐Field MRI for Rapid Detection and Monitoring of ARIA in Lecanemab‐Treated Alzheimer's Disease Patients: A Pilot Study

This pilot study suggests that portable LF MRI can detect and monitor ARIA-E in patients treated with lecanemab, potentially circumventing delays associated with HF MRI. Although image quality is lower than HF MRI, the ability to guide therapeutic decisions promptly may prove clinically significant. Further larger-scale studies are warranted to validate these initial findings, refine imaging protocols, and explore the broader role of LF MRI in routine ARIA screening and follow-up.